{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-014630","form_type":"8-K","ticker":"APTN","cik":"0001938571","company_name":"ADAPTIN BIO, INC.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.608866+00:00","generated_at":"2026-05-26T17:39:14.206420+00:00","sec_items":["2.01","3.02","1.01","3.03","4.01","5.01","5.02","5.03","5.05","5.06","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Adaptin Bio completes reverse merger with private biotech, raises ~$4.76M in private placement","bullets":["Merger between Unite Acquisition (shell) and Private Adaptin closed Feb 11, 2025; Private Adaptin becomes wholly owned subsidiary.","Issued ~3.25M shares to Private Adaptin stockholders; former shell stockholder Lucius Partners retains 3.25M shares.","Concurrent private placement of 1,080,814 Units at $4.40/Unit raised $4,755,581; each Unit: one share, one A warrant, one-half B warrant.","$1.5M bridge notes plus accrued interest converted into 501,140 shares and pre-merger warrants issued.","Company to file resale registration statement within 60 days after offering termination; OTC Markets QB listing planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-014630","json":"https://secwatch.observer/filing/0001213900-25-014630.json","markdown":"https://secwatch.observer/filing/0001213900-25-014630.md","text":"https://secwatch.observer/filing/0001213900-25-014630.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938571/000121390025014630/0001213900-25-014630-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938571/000121390025014630/ea0230169-8k_adaptin.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T17:39:14.206420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a475e7c0bfa39174722403e4f60ae500b93cde63","claim":"ADAPTIN BIO, INC.: Amendment and restatement of certificate of incorporation approved by board on February 11, 2025 and by stockholders on the same date, effective upon the Merger (effective 2025-02-11).","evidence_excerpt":"Prior to the Merger, Unite Acquisition’s board of directors approved the amendment and restatement of our certificate of incorporation on February 11, 2025, and stockholders holding 100% of the then outstanding shares of our Common Stock approved the amendment and restatement to our certificate of incorporation on February 11, 2025.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938571/000121390025014630/0001213900-25-014630-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-02-11"}],"fact_type":"governance_change"},{"claim_id":"b06e226122532ff4c554a2becf139147b4c89275","claim":"ADAPTIN BIO, INC.: Board adopted a new Code of Ethics in connection with the Merger, applying to all directors, officers, and employees.","evidence_excerpt":"In connection with the Merger, the board of directors adopted a new Code of Ethics, which applies to all directors, officers (including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) and employees.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938571/000121390025014630/0001213900-25-014630-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"}],"fact_type":"governance_change"},{"claim_id":"ce7ed941bb0804695e05ea1c721cee5613684310","claim":"ADAPTIN BIO, INC.: Registrant ceased to be a shell company as a result of the Merger.","evidence_excerpt":"As a result of the Merger, we have ceased to be a shell company.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938571/000121390025014630/0001213900-25-014630-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"shell status"}],"fact_type":"governance_change"},{"claim_id":"fcaa67af5c65077254ec04150f61e6ee05f7cea0","claim":"ADAPTIN BIO, INC.: Bylaws amended and restated in their entirety effective upon closing of the Merger.","evidence_excerpt":"Prior to the Merger, we amended and restated our bylaws in their entirety, to be effective upon closing of the Merger.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938571/000121390025014630/0001213900-25-014630-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"1532607139797f7c538128d5377425e8b9ebe2af","claim":"ADAPTIN BIO, INC. underwent a change of control involving Adaptin Bio, Inc. (Private Adaptin) (closed 2025-02-11).","evidence_excerpt":"As a result of the Merger, we acquired the business of Private Adaptin and will continue its business operations as a public reporting company under the same name, Adaptin Bio, Inc.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938571/000121390025014630/0001213900-25-014630-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Adaptin Bio, Inc. (Private Adaptin)"},{"label":"Closing","value":"2025-02-11"}],"fact_type":"ma_transaction"},{"claim_id":"e6b2cae5bf50a1056d465fbaa7f7cf480c63d7bd","claim":"ADAPTIN BIO, INC. completed an acquisition involving Adaptin Bio, Inc. (Private Adaptin) (closed 2025-02-11).","evidence_excerpt":"On February 11, 2025, Unite Acquisition’s wholly-owned subsidiary, Adaptin Acquisition Co., a Delaware corporation formed in the State of Delaware on January 30, 2025 (“Merger Sub”), merged with and into Adaptin Bio, Inc., a privately held Delaware corporation (“Private Adaptin”) formerly known as Centaur Bio Inc.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1938571/000121390025014630/0001213900-25-014630-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Adaptin Bio, Inc. (Private Adaptin)"},{"label":"Closing","value":"2025-02-11"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}